#Israel #Petah Tikva #Heart Failure #Microtech #Medinol

Microtech's Breakthrough in Heart Failure Treatment

In a significant advancement in medical technology, Microtech, a fully owned subsidiary of Medinol Inc., has commenced clinical trials for its innovative implantable microsensor designed to monitor heart failure conditions in humans. This pioneering development, announced on December 26, 2024, is spearheaded by Professor Erez Sharoni at the Beilinson Medical Center in Petah Tikva, Israel.

The new microsensor platform is the culmination of extensive research and development efforts aimed at creating a next-generation sensor technology that can be deployed as a standalone device or integrated into existing medical instruments. The microsensors are remarkably compact, measuring submillimeter in size, and function passively while communicating via ultrasound. This design allows for the transformation of pre-existing implants into smart devices capable of real-time data collection and multi-functionality.

Professor Sharoni highlighted the potential impact of this technology, stating, "This astonishing innovation may redefine the standard of care for patients suffering from heart failure, particularly those receiving left ventricular assist devices (LVAD) or heart transplants." The valuable data yielded from the implanted sensors will assist heart failure specialists in making informed clinical decisions for these patients.

Dr. Tuvia Ben-Gal, head of the Heart Failure Department at Rabin Medical Center, emphasized the importance of this technology by explaining how heart failure often involves periods of stability followed by exacerbations that require repeated hospitalizations. He remarked, "This groundbreaking technology allows us to monitor patient parameters in real-time and intervene promptly to reduce morbidity and mortality among these patients."

The integration of sensors into current medical devices provides physicians with the ability to treat patients based on quantifiable physiological parameters rather than merely their symptoms. According to Dr. Yoram Richter, CEO of Medinol, this marks a pivotal step toward equitable healthcare access globally. He explained, "Using a compact home unit, patients with implants equipped with Microtech technology can provide immediate and highly accurate pressure readings directly to their healthcare provider, thus eliminating geographic barriers or mobility challenges."

This capability is projected to have transformative implications across a wide spectrum of clinical scenarios, impacting patients with various conditions such as heart failure, glaucoma, hydrocephalus, portal hypertension, and endoleaks following abdominal aortic aneurysm (AAA) repairs. The aim is not only to enhance access to healthcare but also to minimize the need for outpatient or emergency visits. Importantly, from the perspective of healthcare providers and device manufacturers, these smart sensor-equipped devices aim to extend the focus beyond acute anatomical interventions to lifelong patient care.

About Medinol

Medinol is committed to reshaping the paradigm in disease diagnostics and treatment. From designing cutting-edge devices for multi-site stenting to significantly reducing complications during structural heart procedures, the company is courageously reevaluating existing technologies while looking ahead to pioneer new products. Collaborating closely with healthcare partners, Medinol aspires to expand the physical and geographic reach of care to patients worldwide.

For more information, please visit www.medinol.com or contact Jeff Roache, Chief Commercial Officer, at [email protected].